Introduction
The Cytochrome P450 is the major enzyme involved in drug metabolism. CYP enzymes are responsible for the metabolism of most clinically used drugs. Individual variability in drug efficacy and toxicity resulting in different clinical responses is common in therapeutic areas, including breast cancer. It is an important problem in clinical practice because it can lead to therapeutic failure and adverse effects. Polymorphisms in the genes encoding enzymes responsible for the metabolism of drugs and other xenobiotics and the functional significance of these polymorphisms are critical for predicting clinical outcomes (Ruiter, et al 2010) .
Tamoxifen, selective estrogen receptor modulators (SERM) is the most commonly prescribed drug for the treatment and prevention of recurrence for patients with estrogen and/or progesterone receptor positive disease.
recruited from the MNJ cancer hospital, Hyderabad, Telangana, India, between January 2014 and October 2016. All patients were diagnosed with breast cancer. Senior pathologists confirmed all diagnoses. The controls were recruited from general population from Hyderabad during the same time period. Each control was matched to each case by age and sex. All subjects were given a questionnaire to investigate the demographic characteristics, family history of cancer. The clinical characteristics were collected from medical records, including tumor differentiation, tumor size and hormonal and chemotherapy. This study was approved by the hospital Ethnical Committee, Hyderabad, and informed consent was obtained from all participants. . Patients were recruited following certain inclusion and exclusion criteria, which were determined before the beginning of the study.
Human Genomic DNA Isolation
Approximately 4ml of blood was collected from all participants, mixed with EDTA and kept at -20°C Genomic DNA was extracted from the blood and isolated using epicenter DNA isolation kit. Isolated DNA was stored in Tris-EDTA buffer, pH 8.0. DNA samples were stored at -20°C till analysis. Their concentrations were determined by a spectrophotometer (Nanodrop Thermo 2000c). The genomic polymorphism was identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique.
Polymerase chain reaction
The primers were synthesized at a commercial facility in Hyderabad (Bioserve, Hyderabad, India). The primers used for amplification of CYP2D6*4, CYP2D6*10, CYP3A5*3 and CYP2C19*2 genes were listed in table -1. PCR was carried out using a PCR kit (Bioserve) in a total volume of 50 μl. The PCR mixture contained 2.5 μl of 25 mM MgCl2, 10 mM dNTP mixture, 160 pmol of each primer (forward and reverse primers), 0.2 μl of Taq (5 U/μl) and a DNA template. The reaction volume was made up to 50 μl with sterile water. The PCR reaction was carried out in a CFX 96 thermocycler (Bio-Rad, Hercules, CA, USA) using the following optimal conditions. Initial denaturation was carried out at 95°C for 5 min, followed by 35 cycles of denaturation at 94°C for 35 sec, annealing at 58°C for 35 sec and extension at 72°C for 40 sec. After completion of 35 cycles, a final extension step was carried out at 72°C for 5 min. Amplification products corresponding to 354bp, respectively, were visualized after electrophoresis in an ethidium-bromide-stained 2% agarose gel. The amplified PCR products were performed RFLP using BstN1, (Fermentas) restriction enzyme for 37°C overnight PCR products subjected to enzyme digestion was visualized on 3% agarose gel stained with ethidium bromide (Figures 1, 2, 3 and 4) .
Statistical analysis
The frequency of genotypes was determined by calculating their percent in the control and cancer groups. Next, the frequency of alleles was obtained in both groups according to the Hardy-Weinberg equilibrium. The fisher's exact test (2×2 only) was performed by using MedCalc software for Windows (version 7.4.1.0; Mariakerke, Belgium) to examine the association of mir polymorphisms between cases and controls and different clinical and pathological parameters. The difference between the groups was considered significant if the p value was 0.05.
Results

Clinical Characteristics of the study population
In the present study 110 blood samples from breast cancer patients and 100 blood samples from healthy controls were used. General characteristics of the breast cancer patients and controls are given in table 1. All 128 subjects were histopathalogical confirmed breast cancer cases and 98 were healthy controls with age and sex matched. Ages ranged from 20-70 years for cases and 22-70 years for controls. Breast cancer patients were divided into 5 groups according to age at diagnosis; Table Below Figure. , when compared to other types. Of the cases, 22% (n= 23) were Grade I, 48% (n= 53) were Grade II and 30% (n=34) were Grade 3. While 26% (n= 29) of the patients were triple negative ER, PR, HER2 (-ve) breast cancer. Of those observed, 57% (n= 63) had received FAC/tamoxifen, 31% (n= 36) had received only FAC and 12% (n= 11) were unknown cases (Table. 2).
CYP2D6*4 (G1934A) Genotype Frequencies
The overall genotype and allele frequencies of CYPs in breast cancer cases and health controls are shown in Table 2 . CYP2D6 gene polymorphisms were classified by metabolizer groups. The frequencies of the EM, IM, and PM genotypes of CYP2D6*4 (G1864A) were 79%, 15%, and 6% in the patients, and 96%, 4%, and 0%, respectively, in the healthy control group. We found significant difference in the frequencies of genotypes (OR: 4.3; 95% CI: 1.4230 to 13.5257, P = 0.01) between Breast Cancer Patients and Controls (Table 3) . Significant difference was found between CYP2D6 IM metabolizer group and age group between 51-60 (p= 0.001), and also ER/PR, HER2 grade and therapy were compared with metabolizer groups of the patients. No statistically significant change was observed across the groups (p= 0.57, p= 0.22, p= 0=0.27, p= 0.44) ( Table 4) .
CYP2D6*10 (C188T) Genotype Frequencies
The frequencies of the CC, CT, and TT genotypes of CYP2D6*10 (C100T) were 75%, 23%, and 2% in the patients, and 92%, 7%, and 1%, respectively, in the healthy control group (Table 2 ). The CT genotype was these were 21-30, 31-40, 41-50, 51-60 and 61-70 years. Incidence of breast cancer cases and a control group was higher in the age groups 41-50 (40% (44 out of 110) years when compared to other age groups. Of the patients, majority of sporadic breast cancer cases were higher in postmenopausal 62% (n= 69) and 41% (n= 38) were (Table 5 ).
CYP3A5*3 (A6986G) Genotype Frequencies
The frequencies of the AA, AG, and GG genotypes of CYP3A5*3 (A6986G) were 88%, 10%, and 2% in the patients, and 95%, 11%, and 2%, respectively, in the healthy control group (Table 2 ). The AG genotype was significantly different between breast cancer patients and control subjects. We show that no difference between the patients and controls for A6986G polymorphism (OR: 2.1; 95% CI: 0.7070 to 6.3041, P = 0.18) ( Table 3) . In the present study we found that ER/PR, HER2, grade and therapy were compared with metabolizer groups of the patients. No statistically significant change was observed across the groups (p= 0.56, p= 0.98 p= 0.11 and 0.09) ( Table 6 ).
CYP2C19*2 (G681A) Genotype Frequencies
The frequencies of the GG, GA, and AA genotypes of CYP2C19*2 (G681A) were 88%, 10%, and 2% in the patients, and 95%, 5%, and 1%, respectively, in the healthy control group (Table 2) .. The GA genotype was significantly different between breast cancer patients and control subjects. Frequency of GA genotype was significantly associated with breast cancer (OR: 3.7; 95% CI: 1.5202 to 9.0425, P = 0.004) ( Table 3 ).. Significant difference was found between CYP2C19*2 GA genotype group and tamoxifen received group (p= 0.03), ER/ PR, HER and grade were compared with CYP2C19*2 genotypes of the patients. No statistically significant change was observed across the groups (p= 0.54, p= 0.97 and 0.11) ( Table 7) .
Distribution genotype frequencies of tamoxifen treated cases
The CYP2D6*4 EM, IM and PM in the tamoxifen treated patients were 57.6% and 38% and 4% respectively and for the CYP2D6*10 EM, IM and PM group were 74%, 13% and 0% respectively and for the CYP3A5*3 EM, IM and PM group were 93%, 7% and 0% and for the CYP2C19*2 EM, IM and PM group were 86%, 14% and 0% (Table 8 a standard treatment to prevent recurrences in women suffering from breast cancer, the drug is still not effective for 20 to 30% of patients receiving it. The important role of cytochrome P450 (CYP) proteins in the metabolism of tamoxifen has led to speculation that polymorphisms in CYP2D6, CYP3A5 and CYP2C19 may contribute to the observed variations in treatment efficacy. The objectives of the present study were to study the pharmacogenetics of CYP3A5, CYP2C9, CYP2C19 and CYP2D6 polymorphisms in south Indian women with breast cancer. CYP2D6 is responsible for the metabolism of tamoxifen to create its active metabolite, endoxifen. CYP2D6*4 and CYP2D6*10 polymorphisms plays an important role in the breast cancer etiology and might help in planning hormonal therapy where tamoxifen is used. In the present study CYP2D6*4 and CYP2D6*10 intermediate and poor metabolizers were significantly associated with south Indian women with breast cancer. Reduced CYP2D6 activity is associated with poor treatment outcomes, in terms of increased risk of recurrence and shorter recurrence free survival, in breast cancer patients on adjuvant tamoxifen therapy. Kiyotani K, Mushiroda, et al 2010, reported patients with poor metabolizers leads to poor survival. The frequency of intermediate metabolizes of CYP2D6*4 and CYP2D6*10 alleles were high in postmenopausal women treated with tamoxifen. This suggests that identifying such patients before the start of treatment may be useful in optimizing therapy with tamoxifen.
Apart from CYP2D6, other cytochrome P450 enzymes (CYP3A5 and CYP2C19) also contribute to the overall metabolism of tamoxifen and its metabolites, albeit to different extents CYP3A5 catalyses the N-demethylation of tamoxifen to NDM or 4-OHT to endoxifen. In the present study CYP3A5*3 was not statistically significant. Our results are consistent with previous studies. Jin et al 2005 and Tucker et al, 2005 did not find any significant association between CYP3A5*3 (6986A>G; rs776746) and the plasma concentrations of tamoxifen and its metabolites. It is likely that the functional impact of CYP3A5*3 (6986A>G; rs776746) on the metabolism of tamoxifen is nullified. CYP2C19*2 was statistically significant (p=0.02). Previous studies have also found the presence of CYP2C19*2 to be associated with elevated efficacy of tamoxifen treatment, this study agrees with the findings of other research (Rikje Ruiter, et al 2009) . The role of CYP3A5 and CYP2C19 seem to be minor.
In the present study the association between genotypes and clinicopathological parameters of breast cancer was also analyzed in our study. It was noted that there was significant association between intermediate metabolizers of CYP2D6 and CYP2C19 and tamoxifen therapy received and grade II patients. It was observed that there was no significant association between CYP2D6 CYP3A5 and CYP2C19 polymorphisms and age, ER/PR, Her2 neu and garde. 15 percent of all breast cancers are triple negative, tamoxifen is not currently used to treat triple negative breast cancer (TNBC). In our study, 26% cases are triple negative breast cancer, the CYP2D6*4, CYP2D6*10, CYP3A5*3 and CYP2C19*2 genes intermediate metabolizer group was showed high frequency but statistically not significant. 
